Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care Market CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
View HTML
Toggle Summary Vericel to Report First-Quarter 2019 Financial Results on May 7, 2019
CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2019 financial results and
View HTML
Toggle Summary Vericel to Present at Needham Healthcare Conference
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Needham
View HTML
Toggle Summary Vericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences. Nick Colangelo, president and CEO will present
View HTML
Toggle Summary Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance
Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017 Full-Year 2018 Product Revenues of $90.9 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in
View HTML
Toggle Summary Vericel to Participate in Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced participation in multiple upcoming investor conferences. Nick Colangelo, president and CEO and Gerard
View HTML
Toggle Summary Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2018 financial results and
View HTML
Toggle Summary Vericel to Present at the 21st Annual Needham Growth Conference
CAMBRIDGE, Mass., Jan. 11, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 21 st Annual
View HTML
Toggle Summary Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research
Results Demonstrate an Increased Survival Rate for Patients Treated with Epicel CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of
View HTML
Toggle Summary Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results
View HTML

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.